EverHint – SMA 20/50 Crossover, EMA 10 + Price + MACD, EMA 10/30 Crossover – Top 22 Buy and Top 10 Sell Signals for Nov 06, 2026
Excerpt: 32 signals (from 83 total). Technology leads (16). price range $7-$927. 4 with insider selling.
SMA 20/50 Crossover
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
🟢 Buy Signals (2 of 2)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | FOX | Fox Corporation | Communication Services | $59.50 | — | — | $26.6B |
| 2 | VRTX | Vertex Pharmaceuticals... | Healthcare | $547.09 | — | — | $138.7B |
🔴 Sell Signals (5 of 8)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | DK | Delek US Holdings, Inc. | Energy | $63.95 | — | — | $3.9B |
| 2 | ECHO | EchoStar Corporation | Communication Services | $94.62 | — | — | $15.0B |
| 3 | ENTG | Entegris, Inc. | Technology | $127.98 | — | — | $19.6B |
| 4 | NAT | Nordic American Tanker... | Industrials | $6.67 | — | — | $1.4B |
| 5 | SEI | Solaris Energy Infrast... | Energy | $57.77 | — | — | $3.8B |
EMA 10 + Price + MACD
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
🟢 Buy Signals (10 of 13)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | EXTR | Extreme Networks, Inc. | Technology | $24.03 | — | — | $3.2B |
| 2 | FLY | Firefly Aerospace Inc. | Industrials | $20.76 | — | — | $3.5B |
| 3 | INBX | Inhibrx Biosciences Inc. | Healthcare | $84.52 | — | — | $1.2B |
| 4 | IONQ | IonQ, Inc. | Technology | $32.62 | — | — | $14.0B |
| 5 | KGC | Kinross Gold Corporation | Basic Materials | $22.24 | — | — | $26.4B |
| 6 | LEU | Centrus Energy Corp. | Energy | $104.60 | — | — | $2.1B |
| 7 | LUNR | Intuitive Machines, Inc. | Industrials | $10.47 | — | — | $2.1B |
| 8 | NXE | NexGen Energy Ltd. | Energy | $8.25 | — | — | $5.5B |
| 9 | PH | Parker-Hannifin Corpor... | Industrials | $917.79 | — | — | $115.7B |
| 10 | RGTI | Rigetti Computing, Inc. | Technology | $11.75 | — | — | $3.9B |
EMA 10/30 Crossover
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
🟢 Buy Signals (10 of 20)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | APP | AppLovin Corporation | Technology | $391.22 | — | — | $119.6B |
| 2 | ARGX | argenx SE | Healthcare | $927.21 | — | — | $55.3B |
| 3 | CGON | CG Oncology Inc. | Healthcare | $75.99 | — | — | $6.7B |
| 4 | CHTR | Charter Communications... | Communication Services | $118.07 | — | — | $15.9B |
| 5 | CHYM | Chime Financial, Inc. ... | Technology | $31.33 | — | — | $11.9B |
| 6 | CTRE | CareTrust REIT, Inc. | Real Estate | $38.21 | — | — | $9.0B |
| 7 | ELVN | Enliven Therapeutics, ... | Healthcare | $49.43 | — | — | $3.6B |
| 8 | GRMN | Garmin Ltd. | Technology | $285.57 | — | — | $55.0B |
| 9 | HSIC | Henry Schein, Inc. | Healthcare | $86.05 | — | — | $9.6B |
| 10 | INSM | Insmed Incorporated | Healthcare | $114.41 | — | — | $25.1B |
🔴 Sell Signals (5 of 40)
| # | Ticker | Company | Sector | Price | Insider | Earnings | MCap |
|---|---|---|---|---|---|---|---|
| 1 | ADBE | Adobe Inc. | Technology | $239.30 | — | — | $93.1B |
| 2 | ADI | Analog Devices, Inc. | Technology | $363.56 | — | — | $176.2B |
| 3 | BJRI | BJ's Restaurants, Inc. | Consumer Cyclical | $55.67 | — | — | $1.2B |
| 4 | BP | BP p.l.c. | Energy | $44.53 | — | — | $116.8B |
| 5 | CRI | Carter's Inc. | Consumer Cyclical | $32.01 | — | — | $1.2B |
Recent Headlines
APP (AppLovin Corporation)
- APP DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages AppLovin Corporation Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action – APP
- APP FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages AppLovin Corporation Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - APP
BP (BP p.l.c.)
- BP says Whiting, Indiana refinery offered to meet union, awaits response
CTRE (CareTrust REIT, Inc.)
- CareTrust REIT Q3 Earnings Call Highlights
- 5 REIT Stocks With Generous Dividends to Consider After Q3 Earnings
DK (Delek US Holdings, Inc.)
- Compared to Estimates, Delek US Holdings (DK) Q3 Earnings: A Look at Key Metrics
KGC (Kinross Gold Corporation)
- Investor Alert: Robbins LLP Informs Investors of the Kinross Gold Corporation Class Action Lawsuit
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.